



Attorney's Docket No.: 07300-025002 / YSRI 414.0 Con.1/SCR 1994P

#6

Amended
4.25.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Burton et al.
Serial No. : 10/079,802
Filed : February 19, 2002
Title : LIGAND CAPTURE-DIRECTED SELECTION OF ANTIBODY

Art Unit : 1648
Examiner : Donna Wortman

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

APR 23 2003

RECEIVED

RESPONSE

In response to the action mailed December 13, 2002, the time for responding having been extended to April 14, 2002, by the accompanying petition and fee under Rule 1.136, please amend the application as follows:

Ex. Note cancelled initial
corr. in the claims:

Please cancel claims *15, 22 and 23* *(Baw)*
15, 22 and 23
15, 22 and 23.

Please amend claims 16, 17, 18, and 21 as follows:

--16. (Twice Amended) An isolated antibody produced by E. coli ATCC 69522.

D2 subg
17. (Amended) The antibody of claim 16, wherein the antibody is an Fb or an Fab fragment.

18. (Amended) The antibody of claim 16, wherein the antibody binds to an antigen selected from the group consisting of a bacterial, a viral, a parasitic, a fungal, a tumor and a self-antigen.

Q1
2
21. (Amended) The antibody of claim 16, wherein the antibody neutralizes infectivity of herpes simplex 1 and herpes simplex 2 virus.--

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

April 14, 2003

Signature

Lucille M. Begalla

Typed or Printed Name of Person Signing Certificate

Lucille M. Begalla